CCT128930

Product Name: CCT128930
CAS No.: 885499-61-6
Chemical Name: CCT128930
Synonyms: CS-447;CCT128930;CCT128930, >=98%;CCT128930 (CCT 128930;4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidin-4-aMine;4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylamine;4-[(4-Chlorophenyl)methyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinamine;4-PiperidinaMine, 4-[(4-chlorophenyl)Methyl]-1-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-
CBNumber: CB82554024
Molecular Formula: C18H20ClN5
Formula Weight: 341.84
MOL File: 885499-61-6.mol

More

Less

CCT128930 Property

Density: 1.39
storage temp.: Store at -20°C
solubility: DMSO : 36.67 mg/mL (107.27 mM; Need ultrasonic)
form: Powder
pka: 13.93±0.50(Predicted)
color: Off-white to yellow
InChI: InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)
InChIKey: RZIDZIGAXXNODG-UHFFFAOYSA-N
SMILES: N1(C2N=CN=C3NC=CC3=2)CCC(CC2=CC=C(Cl)C=C2)(N)CC1

More

Less

Safety

HS Code: 2933399990

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 18194
Product name: CCT128930
Purity: ≥95%
Packaging: 1mg
Price: $44
Updated: 2024/03/01

Cayman Chemical

Product number: 18194
Product name: CCT128930
Purity: ≥95%
Packaging: 5mg
Price: $172
Updated: 2024/03/01

Cayman Chemical

Product number: 18194
Product name: CCT128930
Purity: ≥95%
Packaging: 10mg
Price: $321
Updated: 2024/03/01

Cayman Chemical

Product number: 18194
Product name: CCT128930
Purity: ≥95%
Packaging: 50mg
Price: $1027
Updated: 2024/03/01

TRC

Product number: C227955
Product name: CCT128930
Packaging: 5mg
Price: $270
Updated: 2021/12/16

More

Less

CCT128930 Chemical Properties,Usage,Production

Uses

CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM.

Uses

CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2.

in vivo

CCT128930 (25 or 40 mg/kg; i.p. daily or twice daily for 5 days) shows antitumor activities in U87MG and BT474 human breast cancer xenografts^[1].
Summary of the pharmacokinetic parameters of CCT128930 (25 mg/kg) in CrTacNCr-Fox1nu mice^[1]

Tissue	Route	T_1/2 (h)	T_max (h)	C_max (μM)	V_ss (L)	Cl (L/h)	AUC_0-∞ (μMh)	Bioavailability (%)
Plasma	i.v.	0.95	0.083	6.36	0.25	0.325	4.62	100
Plasma	i.p.	2.33	0.5	1.28	N/A	0.372	1.33	28.8
Tumor	i.p.	3.89	1	8.02	N/A	0.06^*	25.8	N/A
Plasma	p.o.	0.57	0.5	0.432	N/A	0.317	0.392	8.5

^*Apparent clearance.

Animal Model:	6-8 weeks old female CrTacNCr-Fox1nu mice^[1]
Dosage:	25 mg/kg (U87MG human glioblastoma xenografts) or 40 mg/kg (BT474 human breast cancer xenografts)
Administration:	i.p. daily for 5 days (U87MG human glioblastoma xenografts); i.p. twice daily for 5 days (BT474 human breast cancer xenografts)
Result:	Giving a treated:control (T/C) ratio on day 12 of 48%. There was no weight loss associated with this regime in U87MG human glioblastoma xenografts. Had a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. This regimen was associated with minimal weight loss, with a nadir of only 94.8% of the initial body weight on day 15 of treatment in BT474 human breast cancer xenografts.

target

Akt2

IC 50

Akt2: 6 nM (IC₅₀); p70S6K: 120 nM (IC₅₀); PKA: 168 nM (IC₅₀); Autophagy; Apoptosis

CCT128930 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

CCT128930 Suppliers

China 93 United Kingdom 1 United States 14 Global 108

Apollo Scientific Ltd.

Tel: --
Fax: --
Email: sales@apolloscientific.co.uk
Country: United Kingdom
ProdList: 6084
Advantage: 88

885499-61-6, CCT128930Related Search:

CC-122 CCT 137690 CCG215022 CC-92480 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- CC-885 CCT245737 CCF-642 (S)-(+)-Benzyl glycidyl ether 2-Methylpropanedioic acid Benzyl alcohol Poly(methyl methacrylate) 4'-Hydroxyacetophenone Everolimus 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol MK-2206 2HCl A-674563 PF-04691502

4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)piperidin-4-aMine

CCT128930 (CCT 128930

CS-447

4-[(4-Chlorophenyl)methyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinamine

4-PiperidinaMine, 4-[(4-chlorophenyl)Methyl]-1-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-

CCT128930, >=98%

CCT128930

4-(4-Chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylamine

885499-61-6

C18H20ClN5

Akt

mTOR

PI3K

Inhibitors